Pages that link to "Q43673455"
Jump to navigation
Jump to search
The following pages link to Pharmacokinetics of zidovudine and lamivudine in neonates following coadministration of oral doses every 12 hours (Q43673455):
Displaying 25 items.
- The last and first frontier--emerging challenges for HIV treatment and prevention in the first week of life with emphasis on premature and low birth weight infants. (Q30382184) (← links)
- Getting to 90-90-90 in paediatric HIV: What is needed? (Q30385352) (← links)
- Protecting the fetus against HIV infection: a systematic review of placental transfer of antiretrovirals (Q34429204) (← links)
- Developmental pharmacokinetics of lamivudine in 580 pediatric patients ranging from neonates to adolescents (Q35065937) (← links)
- Nelfinavir and Lamivudine pharmacokinetics during the first two weeks of life (Q35171059) (← links)
- Neonatal liver failure (Q35682625) (← links)
- Developmental pharmacokinetic changes of Lamivudine in infants and children (Q36013430) (← links)
- Maternal adherence to the zidovudine regimen for HIV-exposed infants to prevent HIV infection: a preliminary study (Q36031465) (← links)
- Pharmacokinetics of antiretroviral therapy in HIV-1-infected children (Q36240749) (← links)
- Pharmacotherapy of pediatric HIV infection (Q36301325) (← links)
- Population pharmacokinetics of lamivudine in human immunodeficiency virus-exposed and -infected infants (Q36313247) (← links)
- High levels of zidovudine (AZT) and its intracellular phosphate metabolites in AZT- and AZT-lamivudine-treated newborns of human immunodeficiency virus-infected mothers (Q36744874) (← links)
- Nucleoside and nucleotide reverse transcriptase inhibitors in children (Q36885640) (← links)
- Role of ABC and Solute Carrier Transporters in the Placental Transport of Lamivudine. (Q37203806) (← links)
- Optimizing pediatric dosing: a developmental pharmacologic approach (Q37498862) (← links)
- Drug labeling and exposure in neonates (Q37591097) (← links)
- Pharmacokinetics of zidovudine dosed twice daily according to World Health Organization weight bands in Ugandan HIV-infected children (Q37708677) (← links)
- Covariate effects and population pharmacokinetics of lamivudine in HIV-infected children (Q37731863) (← links)
- Antiretroviral Pharmacology: Special Issues Regarding Pregnant Women and Neonates (Q37809609) (← links)
- Pharmacokinetic optimization of antiretroviral therapy in children and adolescents (Q37835819) (← links)
- British HIV Association guidelines for the management of HIV infection in pregnant women 2012 (2014 interim review). (Q38325427) (← links)
- Dose evaluation of lamivudine in human immunodeficiency virus-infected children aged 5 months to 18 years based on a population pharmacokinetic analysis. (Q38771392) (← links)
- Prevention and treatment of HIV infection in neonates: evidence base for existing WHO dosing recommendations and implementation considerations. (Q45932455) (← links)
- British HIV Association guidelines for the management of HIV infection in pregnant women 2012 (Q57076282) (← links)
- Could Postnatal Age-Related Uridine Diphosphate Glucuronic Acid Be a Rate-Limiting Factor in the Metabolism of Morphine During the First Week of Life? (Q91683088) (← links)